Yangzong Pharmaceutical Co., Ltd. in Qinghai Province has developed the extract of Rehmannia glutinosa "Catalpol" into a new hypoglycemic drug

A new research result from Qinghai Provincial Department of science and technology shows that Catalpol, a common ingredient in traditional Chinese medicine Rehmannia glutinosa, can effectively treat diabetes, and its effect is better than that of traditional chemicals In 2006, Qinghai Province set up a scientific and technological innovation platform in Qinghai Yangzong Pharmaceutical Co., Ltd in the way of combination of production, learning and research In 2011, academician workstation was built Academician Liu Changxiao of Chinese Academy of Engineering led researchers from Tianjin Pharmaceutical Research Institute, National Key Laboratory of theoretical chemistry of Jilin University and other scientific research units to carry out new diabetes drug research and development for nearly 10 years At the same time, with the development of key equipment as the key point, we have overcome the technical difficulties of industrialization, and built the first domestic production line of extracting Catalpol from Rehmannia glutinosa with an annual output of 20 tons The researchers extracted Catalpol, an effective component in fresh rehmannia glutinosa, and found that Catalpol was absorbed rapidly in patients, with an absolute bioavailability of 66.9% Catalpol has the advantages of quick onset, rapid and complete excretion, no accumulation in the body, no damage to large organs, meeting the requirements of diabetes indications of long-term administration and no interaction with other drugs It is also found that Catalpol is a kind of traditional Chinese medicine hypoglycemic drug with controllable quality, stable preparation, definite curative effect and less side effects, which is suitable for the treatment of type 2 diabetes It is understood that at present, the hypoglycemic drugs in the market are temporarily dominated by western medicine, and Catalpol drugs with the characteristics of multi mechanism action of reducing blood sugar and lipid, improving insulin resistance will have a very broad market prospect At present, researchers have completed all preclinical studies of drugs, and relevant production processes of enterprises have passed safety evaluation New drugs will soon bring good news to diabetic patients.